Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by University of Arkansas
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01621672
First received: May 31, 2012
Last updated: July 11, 2014
Last verified: July 2014

May 31, 2012
July 11, 2014
April 2010
April 2015   (final data collection date for primary outcome measure)
Duration of complete or near complete response w/ Revlimid therapy compared to group with no Revlimid therapy [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01621672 on ClinicalTrials.gov Archive Site
Toxicities associated with Revlimid versus no further Revlimid treatment [ Time Frame: 3 years ] [ Designated as safety issue: No ]
In qualitative and quantitative terms in context of pre-treatment parameters, in terms of platelet count and peripheral neuropathy
Same as current
Not Provided
Not Provided
 
Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
Myeloma Cure Project: Prospective, Randomized Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Who Have Completed 3 Years of VTD/TD or VTD or VRD Maintenance on Total Therapy 3 (TT3) Trials 2003-33 and 2006-66

The purpose of this study is to determine in a phase II trial, whether further maintenance therapy with Revlimid can extend the duration of progression-free survival and the duration of complete or near complete response compared to no further therapy beyond the TT3 protocol-prescribed 3 years of maintenance with 1 year of VTD plus 2 years with TD, 3 years with VTD (2003-33) or VRD (2006-66).

Determine the associated toxicities in qualitative and quantitative terms using NCI CTCAE(NCI common terminology for adverse events)

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
Drug: Revlimid
10 mg/day in the morning same time each day
Other Name: Lenalidomide
  • Experimental: Revlimid
    Revlimid dosing will be in the morning at the same time each day
    Intervention: Drug: Revlimid
  • No Intervention: No further treatment or observation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female participants of all races/ethnicities with multiple myeloma previously enrolled on UARK 2003-33 or 2006-66.
  • Participant has completed 3 years of maintenance therapy with one of the three study drugs of VTD or VRD and disease status has remained event free (includes patients who prematurely discontinued maintenance therapy as long as 3 years have elapsed since beginning of maintenance).
  • All patients must be ages 18 years of age or greater at the time of signing the informed consent form.
  • Participant has adequate hematopoietic reserve, defined as platelets > 50,000/μL (in participants with bone marrow hypoplasia, remaining peripheral blood progenitor cells can be infused to boost hematopoietic reserve prior to enrollment).
  • Participant has adequate renal function defined as serum creatinine < 3 mg/dL prior to enrolling on study
  • Total bilirubin ≤ 1.5 mg/dL prior to enrolling on study
  • AST (SGOT) and ALT (SGPT) ≤ 2 x ULN prior to enrolling on study
  • Patient must have signed an IRB-approved informed consent and understand the investigational nature of the study.
  • All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®
  • Pregnant or nursing women may not participate. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within
  • 24 hours of prescribing Revlimid® (lenalidomide; prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking Revlimid® (lenalidomide).
  • FCBP must also agree to ongoing pregnancy testing.
  • Lactating females must agree that they will not breastfeed.
  • Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix: Risks of Fetal Exposure,
  • Pregnancy Testing Guidelines and Acceptable Birth Control Methods † A female of childbearing potential is a sexually mature woman who:

    • has not undergone a hysterectomy or bilateral oophorectomy
    • has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Exclusion Criteria:

  • Any condition that the PI believes, laboratory abnormality, or psychiatric illness that would prevent the subject from being enrolled in the research study.
  • Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking Revlimid®)
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental drug or therapy within 28 days of baseline.
  • Known hypersensitivity to thalidomide.
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Concurrent use of other anti-cancer agents or treatments.
  • Known positive for HIV or infectious hepatitis, type B or C.
Both
18 Years and older
No
Contact: Nathan Petty 501-526-6990 ext 2435 pettynathanm@uams.edu
United States
 
NCT01621672
UARK 2009-09
Yes
University of Arkansas
University of Arkansas
Not Provided
Principal Investigator: Bart Barlogie, MD, PhD UAMS Myeloma Institute for Research & Therapy
University of Arkansas
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP